3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Lymphoma, T-Cell, Peripheral
12
Lymphoma, T-Cell
6
Recurrence
5
Lymphoma
5
Lymphoma, Non-Hodgkin
4
Sezary Syndrome
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Smoking
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoproliferative Disorders
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Interventions
Azacitidine
14
venetoclax
10
AP 1903 reagent
7
Rituximab
6
Dexamethasone
6
Itraconazole
5
Cytarabine
5
Bortezomib
5
fludarabine
4
fedratinib
4
belinostat
4
Nivolumab
4
Lenalidomide
4
Imatinib Mesylate
4
Daunorubicin
4
ARQ531
4
pomalidomide
3
ibrutinib
3
daratumumab
3
cc-486
3
angiotensin I (1-7)
3
Standard of Care
3
GSK2110183
3
Cyclophosphamide
3
zanubrutinib
2
tosedostat
2
tazemetostat
2
tanespimycin
2
talquetamab
2
tafasitamab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Neoplasms
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT07036133
2026-02-11
SPI-FOL-102
Acrotech Biopharma Inc.
Phase 1
Recruiting
24 enrolled